In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on Neoleukin Therapeutics (NLTX – Research Report), with a price target of $21.00. The company’s shares closed last Friday at $11.97. According to TipRanks.com, Goldstein is